Replies to post #468616 on Anavex Life Sciences Corp (AVXL)

[sab63090]

Abe:
You gave a nice summary of what Missling has forecast as far as a timeline is concerned with everything pointing to the second half of 2024, thanks for that!

It seems that Missling is getting squeezed just like the can of spinach that Popeye always has in his hand when under stress, the problem is that based on his habitual failed timelines and promises the market fails to respect him at all! He actually seems to ignore normal protocols that are common...that's not good!

Based on my lack of knowledge of how long these things actually take, I try to use common sense and fall back on my training with some disappointments along the way. Important news changes my sense of market flow etc....momentum helps but comes in spurts and has not been long lasting; the trains starts then runs out of fuel or larger trading groups and mm's just slap us around.

This is not a company that has anything on the market to generate profits so I guess it's just waiting on proof of data being excellent.

[kevindenver]

Indeed and with "story" specific news on deck, it should bring in both investors and traders to play out their biases for the year.
More participation by retail = less influence by MM's

I expect a major theme to be the "Missling always misses" versus the maybe Anavex executes camps.

[kund]

Don't worry, the timeline will be revised to H1 2025 in the next conference call. Misleading enjoys flexibility, and shifting the goalposts is his expertise. Right now he is on vacation, he deserves 364 days of vacation for his hard work.

[abew4me]

Even Doc thinks that Anavex 371 is "an excellent candidate for schizophrenia" (See his quote below)

Quote from Doc 328..."If doing a standard 3 + 3 MAD for part A sounds like 5 people enrolled to date with the 6th one identified. If no significant AE, they can move to the next dose soon. They should be able to start Part B by end of the year. Unless they open up additional sites for the Part B, May 2025 will be a challenge.

.....I think 3-71 in schizophrenia is an excellent candidate for schizophrenia.
I also think Missling with his penny wise pound foolish management style is setting up another phase 2 that is too small to properly guide phase 3 and will leave more questions than answers ultimately delaying possible regulatory success (compare to Karuna's SP quintupled after their successful 182 patient phase 2 because it was adequate sized adding about 2B in MC in one day November 2019 that was quickly followed by two efficient phase 3 studies)"

********************************************************************************************
Quote from Dr. Missling...With respect to ANAVEX3-71, we are quite pleased to provide an update that the placebo-controlled Phase 2 clinical trial of ANAVEX3-71 for the treatment of schizophrenia. The study is well underway with the first cohort of schizophrenia patients being fully enrolled. We are also expecting further peer-reviewed clinical publications in both -- involving both ANAVEX2-73 and ANAVEX3-71.